Welcome to the European Association for Cancer Research
Connecting cancer researchers together
EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway
Virtual Event, Worldwide : 11 - 12 February 2025
Scientific programme
To download and print the programme, use the links below.
Listed times are in Central European Time (CET)
WELCOME TO DAY ONE
Chair: Marco Hofmann
OPENING KEYNOTE LECTURE
Piro Lito Memorial Sloan Kettering Cancer Center, USA
Q&A 13:40-13:55
Miriam Molina Arcas Francis Crick Institute, UK
"Rational approaches to combine KRAS inhibitors and immunotherapies"
Q&A 14:15-14:25
Proffered Paper 1
Q&A 14:35-14:40
REFRESHMENT BREAK
Chair: Anna Obenauf
Sandra Misale John Hopkins University, USA
"Mechanisms of sensitivity and resistance to RAS-MAPK pathway inhibition in solid tumors"
Q&A 15:20-15:30
Proffered Paper 2
Q&A 15:40-15:45
Mallika Singh Revolution Medicines, USA
“Targeting the Oncogenic State of RAS with Tri-Complex Inhibitors"
Q&A 16:05-16:15
POSTER SPOTLIGHTS
TRANSITION BREAK
VIRTUAL POSTER SESSION ONE
Listed times are in Central European Time (CET)
VIRTUAL POSTER SESSION TWO
WELCOME TO DAY TWO
Chair: Chiara Ambrogio
Marco Hofmann Boehringer Ingelheim, Austria
"Targeting the RAS Signaling Pathway: Inhibitors and Mechanisms of Resistance"
Q&A 14:25-14:35
Alberto Bardelli University of Torino, Italy
"Adaptive cancer mutability in response to targeted therapies"
Q&A 14:55-15:05
Proffered Paper 3
Q&A 15:15-15:20
REFRESHMENT BREAK
Chair: René Bernards
Marina Pasca di Magliano University of Michigan Medicine School, USA
"Oncogenic KRAS mediated regulation of the pancreatic cancer microenvironment"
Q&A 16:00-16:10
Proffered Paper 4
Q&A 16:20-16:25
CLOSING KEYNOTE LECTURE
Colin Lindsay Manchester Cancer Research Centre, UK
“Channelling patient models and data for validation of clinical vulnerabilities in RAS-mutant lung cancer”
Q&A 16:55-17:10
DISCUSSION SESSION
René Bernards, Anna Obenauf, Marco Hofmann & Chiara Ambrogio
“New challenges for old therapeutic targets: What's next?"
SUMMARY AND CLOSE
